FIELD: chemistry.
SUBSTANCE: invention relates to organic chemistry, specifically an imidazopyridine derivative of formula I or a pharmaceutically acceptable salt thereof, where Y is an oxygen or sulfur atom, a SO2 or -NR19 group, where R19 represents a hydrogen atom or a C1-C6 alkyl group; R1, Ra, Rb and Rc represent independently of each other a hydrogen atom; a halogen atom; -O(C1-C6alkyl) group; R2 represents a hydrogen atom; C1-C6alkyl group substituted with -OH group; (C1-C6alkyl)COOR8, where R8 represents a hydrogen atom or C1-C6alkyl group, said alkyl group being optionally substituted with -NH2 or -OH; (C1-C6alkyl)CONHR9, where R9 represents a -OH group; C1-C6alkyl group; -O(C1-C6alkyl) group; a pyridyl group; -(C=NH)NHCOO(C1-C6alkyl) group; group -(C=NH)NH2 or -(C1-C6alkyl)NR10R11, where R10 and R11 are independently of one another C1-C6alkyl group; (C1-C6alkyl)CO morpholine group; -C(=O)R12, where R12 is -O(C1-C6alkyl) group; C1-C6alkyl group optionally substituted with -OH; a morpholine group; NH-phenyl group, wherein said phenyl group is optionally substituted with -COOH or -COO(C1-C6alkyl) group; or -NR13R14, where R13 and R14 are independently of one another C1-C6alkyl group; (C1-C6alkyl) phenyl group, said phenyl group being substituted with a -CN group; (C1-C6alkyl)thiophenyl group; a phenyl group, said phenyl group being optionally substituted with 1 group, which is selected from -COOH, -COO(C1-C6alkyl), C1-C6alkyl substituted with -OH, -CN, -CONHOH, -NHSO2(C1-C6alkyl) or a -CONH-(C1-C6alkyl)NR15R16, where R15 and R16 are independently of one another C1-C6alkyl group; a pyridyl group; dihydrothiazolyl group; tetrahydrofuranone group substituted with 2 C1-C6alkyl groups; -SO2(C1-C6alkyl) group; R3 represents a phenyl group or a 5-6 member heteroaryl group containing 1 heteroatom selected from nitrogen and sulfur, wherein said phenyl group is optionally substituted with 1 to 2 groups that are selected from -C1-C6alkyl, wherein said alkyl group is optionally substituted with three halogen atoms, preferably F, or a -CN group; a halogen atom, preferably F, -O(C1-C6alkyl), wherein said alkyl group is optionally substituted with 2 to 3 halogen atoms, preferably F; -CN; -OH; -NO2; -COOH; NR17R18, where R17 and R18 are independently of one another C1-C6alkyl group; or -NHCO-(C1-C6alkyl). Invention also relates to a pharmaceutical composition based on compound of claim 1.
.
EFFECT: novel imidazopyridine derivatives having hypoglycemic activity were obtained.
11 cl, 26 tbl, 33 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOUNDS | 2020 |
|
RU2840815C2 |
| CONDENSED DERIVATIVES OF IMIDAZOLE AND PYRAZOLE AS MODULATORS OF ACTIVITY TNF | 2014 |
|
RU2686117C1 |
| FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
| IMIDAZOPYRIDINE COMPOUNDS AS PAD INHIBITORS | 2018 |
|
RU2782743C2 |
| NOVEL COMPOUNDS OF SUBSTITUTED N-(3-FLUOROPROPYL)PYRROLIDINE, METHODS FOR PRODUCTION THEREOF AND THERAPEUTIC APPLICATION THEREOF | 2017 |
|
RU2742278C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | 2012 |
|
RU2648997C2 |
| MODULATORS OF ATP-BINDING TRANSPORTERS | 2010 |
|
RU2552353C2 |
| (AZA)INDOLE-, BENZOTHIOPHENE- AND BENZOFURAN-3-SULPHONAMIDES | 2017 |
|
RU2767904C2 |
| CONDENSED QUINOLINE DERIVATIVE AND USE THEREOF | 2005 |
|
RU2384571C2 |
| CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN TREATING PSYCHOTIC DISORDERS | 2011 |
|
RU2586974C2 |
